Patents Assigned to Valorisation-Recherche, Societe en Commandite
-
Patent number: 8623372Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.Type: GrantFiled: March 26, 2010Date of Patent: January 7, 2014Assignee: Valorisation-Recherche, Societe En commanditeInventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
-
Patent number: 8202847Abstract: Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.Type: GrantFiled: November 10, 2008Date of Patent: June 19, 2012Assignees: The Trustees of the University of Pennsylvania, Valorisation-Recherche, Societe En CommanditeInventors: David B. Weiner, Michael G. Agadjanyan, Rafick P. Sekaly, Mark Holterman
-
Publication number: 20110144281Abstract: The present invention relates to a polymer comprising a cholane core having at least one derivatizable group covalently bonded thereto and a hydrophilic polymer chain covalently bonded to derivatizable group(s) and a process for producing it The present invention also relates to micellar aggregate formed from the polymer of the present.Type: ApplicationFiled: December 5, 2008Publication date: June 16, 2011Applicant: VALORISATION-RECHERCHE, SOCIETE EN COMMANDITEInventors: Xiao-Xia Zhu, Juntao Luo, Guillaume Giguere
-
Patent number: 7785567Abstract: According to the invention there is provided a method of treatment or prophylaxis of atherosclerosis, hypercholesterolemia or a cardiovascular disease associated with atherosclerosis, which method comprises administration of one or more Growth Hormone Releasing Peptides (GHRPs) to a patient in need of such treatment or prophylaxis. There are also provided methods of reducing blood plasma cholesterol levels, as well as methods of modulating the expression of the scavenger receptor CD36 and genes involved in cellular cholesterol efflux.Type: GrantFiled: August 21, 2003Date of Patent: August 31, 2010Assignees: Valorisation-Recherche, Société en Commandite, Valorisation HSJ, Société en CommanditeInventors: Huy Ong, Sylvie Marleau, André Tremblay
-
Patent number: 7727531Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.Type: GrantFiled: October 24, 2008Date of Patent: June 1, 2010Assignee: Valorisation-Recherche, Societe En commanditeInventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
-
Publication number: 20100041609Abstract: Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease as well as other chronic or acute inflammatory diseases.Type: ApplicationFiled: October 15, 2009Publication date: February 18, 2010Applicant: Valorisation-Recherche, Societe en CommanditeInventors: Sylvain Chemtob, Christiane Quiniou, William D. Lubell, Martin Beauchamp, Karl A. Hansford
-
Publication number: 20080312549Abstract: There is provided a system and a method for quantitative measurement of spasticity in a patient. It has been found that stretch reflex measurements, that are quantitatively indicative of spasticity, can be obtained by recording an EMG signal while the limb is being moved at a variety of angular velocities. The method advantageously allows the clinician to perform the test at the bedside by eliminating the need for cumbersome mechanical components for moving the limb while providing quantitative measurements.Type: ApplicationFiled: March 31, 2006Publication date: December 18, 2008Applicants: VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE, MCGILL UNIVERSITYInventors: Mindy Levin, Anatol Feldman, Eric Johnstone
-
Patent number: 7446189Abstract: Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.Type: GrantFiled: April 27, 2000Date of Patent: November 4, 2008Assignees: Institut de Recherches Cliniques de Montreal, The Trustees of the University of Pennsylvania, Valorisation-Recherche, Societe en CommanditeInventors: David B. Weiner, Michael G. Agadjanyan, Rafick P. Sekaly, Mark Holterman
-
Patent number: 7445782Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.Type: GrantFiled: March 14, 2002Date of Patent: November 4, 2008Assignee: Valorisation-Recherche, Societe en CommanditeInventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
-
Publication number: 20070169214Abstract: TMT-based methods for the selection of transgenic cells and the production of transgenic organisms are described herein. The toxin used in the selection methods is a TMT substrate. Also described herein are the recombinant cells, plants and progeny and seeds thereof having the TMT gene, a selectable marker system based on the TMT gene, and commercial packages relating to a TMT-based selectable marker system.Type: ApplicationFiled: March 10, 2005Publication date: July 19, 2007Applicant: VALORISATION-RECHERCHE, SOCIETE EN COMMANDITEInventors: Hargurdeep Saini, Kumari Koonjul, Jihad Attieh
-
Publication number: 20050203270Abstract: Disclosed is a polymer of the formula I: wherein: Z is —O— or —NH—; R1 represents a non-functional backbone of a hydroxy acid or amino acid derived from a cyclic ester or diester or cyclic amide or diamide monomer (A); R2 represents a non-functional chain derived from an epoxide monomer (B), said chain ending with a graftable hydroxy or carboxylic group; n is the number of units derived from the monomers (A); m is the number of units derived from the monomers (B); and x is equal to n+m, the ratio m/x ranging from 0.005 to 0.30. Also disclosed is a process of preparing this functionalizable polymer to the hydroxy or carboxylic groups of which can be grafted a compound selected from the group consisting of: ligands specific to cellular receptors, such as Selectine E; lipids; peptides; polyethers; polyacrylates; natural polymers; polyosides; antigens or antibodies; salen; and cyclodextrins. The so grafted polymer can be used as carried or excipient in the biomedical and pharmaceutical fields.Type: ApplicationFiled: April 3, 2003Publication date: September 15, 2005Applicant: Valorisation-Recherche, Societe en CommanditeInventors: Patrice Hildgen, Gregoire Leclair, Richard Quesnel